2 weeks Ago By Defense World Staff
Wells Fargo & Company MN lifted its position in Laureate Education, Inc. (NASDAQ:LAUR – Free Report) by 20.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC.
The firm owned 112,136 shares of the company’s stock after purchasing an additional 18,695 shares during the quarter. Wells Fargo & Company MN owned about 0.07% of Laureate Education worth $2,051,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of LAUR. Asset Management One Co. Ltd.
lifted its holdings in shares of Laureate Education by 21.6% in the 4th quarter. Asset Management One Co.
Ltd. now owns 76,317 shares of the company’s stock worth $1,390,000 after acquiring an additional 13,540 shares during the last quarter. Charles Schwab Investment Management Inc.
lifted its position in Laureate Education by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc.
now owns 2,181,073 shares of the company’s stock valued at $39,892,000 after buying an additional 35,521 shares during the period. Burney Co. bought a new stake in Laureate Education during the fourth quarter worth about $666,000.
Raymond James Financial Inc. purchased a new position in Laureate Education during the fourth quarter valued at $408,000. Finally, KBC Group NV boosted its stake in Laureate Education by 48.
4% in the 4th quarter. KBC Group NV now owns 6,049 shares of the company’s stock worth $111,000 after purchasing an additional 1,974 shares in the last quarter. 96.
27% of the stock is currently owned by institutional investors. Laureate Education Stock Up 0.7 %Laureate Education stock opened at $19.
74 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.
63 and a current ratio of 0.63. The stock has a market cap of $2.
98 billion, a PE ratio of 10.18 and a beta of 0.43.
The stock has a fifty day moving average of $19.54 and a 200 day moving average of $18.67.
Laureate Education, Inc. has a one year low of $13.26 and a one year high of $21.
73. Laureate Education (NASDAQ:LAUR – Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported $0.
62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.20.
Laureate Education had a net margin of 18.92% and a return on equity of 32.35%.
The firm had revenue of $423.40 million during the quarter, compared to the consensus estimate of $411.50 million.
As a group, sell-side analysts predict that Laureate Education, Inc. will post 1.51 EPS for the current year.
Insiders Place Their BetsIn other news, Director Ian Kendell Snow sold 520,831 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $17.47, for a total value of $9,098,917.
57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.
20% of the stock is owned by company insiders. Analysts Set New Price TargetsSeparately, BMO Capital Markets upped their price target on Laureate Education from $21.00 to $23.
00 and gave the company an “outperform” rating in a report on Monday, February 24th.Read Our Latest Stock Analysis on Laureate EducationLaureate Education Profile (Free Report)Laureate Education, Inc, together with its subsidiaries, offers higher education programs and services to students through a network of universities and higher education institutions. The company provides a range of undergraduate and graduate degree programs in the areas of business and management, medicine and health sciences, and engineering and information technology through campus-based, online, and hybrid programs.
See AlsoFive stocks we like better than Laureate EducationHow to Calculate Inflation RateShort Sellers Gave Up on These 3 Names RecentlyWhat is a Secondary Public Offering? What Investors Need to Know3 Boring Stocks Outperforming the Market This YearWhat is the NASDAQ Stock Exchange?If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy.
